Enzo Biochem, Inc. v. Harbert Discovery Fund, LP

CourtDistrict Court, S.D. New York
DecidedSeptember 27, 2021
Docket1:20-cv-09992
StatusUnknown

This text of Enzo Biochem, Inc. v. Harbert Discovery Fund, LP (Enzo Biochem, Inc. v. Harbert Discovery Fund, LP) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Enzo Biochem, Inc. v. Harbert Discovery Fund, LP, (S.D.N.Y. 2021).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

------------------------------------------------------------X : ENZO BIOCHEM, INC., : : Plaintiff, : : -against- : : 20-cv-9992 (PAC) HARBERT DISCOVERY FUND, LP, : HARBERT DISCOVERY CO- : INVESTMENT FUND I, LP, HARBERT : OPINION & ORDER FUND ADVISORS, INC., HARBERT : MANAGEMENT CORP., and KENAN : LUCAS, : : Defendants. : : ------------------------------------------------------------X

Plaintiff Enzo Biochem, Inc. (“Enzo” or “Company”) brings this action pursuant to Section 14(a) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 14a-9 promulgated thereunder against Defendants Harbert Discovery Fund, LP, Harbert Discovery Co- Investment Fund I, LP, Harbert Fund Advisors, Inc., Harbert Management Corp., and Kenan Lucas (collectively “Harbert”). The Complaint alleges that, between 2019 and 2020, Harbert promulgated materially false and misleading proxy solicitations in order to elect two of its nominees to the Company’s board of directors. Harbert moves to dismiss this case pursuant to Rules 12(b)(1) and (b)(6) of the Federal Rules of Civil Procedure, raising both procedural and substantive arguments in support of its motion. For the reasons set forth below, the motion is GRANTED in part and DENIED in part. BACKGROUND I. Harbert’s Introduction to Enzo The following factual account is drawn from the Complaint and assumed to be true for purposes of resolving this motion. Plaintiff Enzo is a publicly listed life sciences and biotechnology company that is incorporated and headquartered in New York. (Compl. ¶¶ 1, 11,

ECF 2.) Enzo was founded in 1976, and today, it operates through three business divisions: Clinical Laboratory, Life Sciences, and Therapeutics. (Id. ¶¶ 17–18.) The core of Enzo’s business consists of developing and manufacturing advanced biotechnology solutions and platforms—for example, COVID testing kits and medical treatments for gastrointestinal diseases—and bringing those products and treatments to market. (Id.) Defendant Harbert is comprised of a consortium of affiliated investment funds and their portfolio manager, Kenan Lucas. (Id. ¶¶ 11–16.) Harbert conducts its financial activities from its headquarters in Birmingham, Alabama. (Id.) It invests in various portfolio companies using an activist investment strategy. (Id. ¶ 20.) Under that strategy, Harbert “targets illiquid small or

micro-cap companies for investment, and attempts to install its appointees on the boards of those companies” in order to effectuate management strategies that are in its interests. (Id.) Beginning in 2018, Harbert expressed an interest in investing in Enzo and, to that end, met with Company management on several occasions to discuss its “history, strategy, and financial performance.” (Id. ¶ 22.) Until that point, Harbert had no experience investing in the life sciences and biotechnology industries. (Id. ¶ 21.) Yet, following these interactions, Harbert began investing in Enzo and by 2019, it emerged as Enzo’s largest shareholder, having bought up nearly 12% of the Company’s shares. (Id. ¶ 23.) II. The Proxy Contest On May 28, 2019, Harbert began to seek corporate governance reform within the Company. (Id. ¶ 24.) In particular, Harbert made the following three corporate governance demands: (1) that Enzo replace two of its incumbent directors with nominees selected by Harbert, (2) that Enzo declassify its board of directors (“Board”), and (3) that it install Kenan

Lucas in a “Board observer role.” (Id.) The central dispute in this case stems from the first of these demands. In 2019, at the time Harbert’s demands were made, two of the five seats on the Board were occupied by Barry Weiner and Bruce Hanna.1 (Compl. ¶¶ 24–26.) Directors Weiner and Hanna, however, were up for reelection at the 2019 Annual Meeting of Shareholders (“2019 Meeting”), which was scheduled for January 31, 2020. (Id.) At the 2019 Meeting, Harbert sought to fill these two seats with its own nominees. (Id.) But Harbert’s private negotiations with the Company regarding its corporate governance demands proved unsuccessful. (Id. ¶ 27.) So, in September 2019, Harbert launched a proxy

contest against the Company to fill the two Board seats at the upcoming 2019 Meeting. (Id.) Through the proxy contest, Harbert sought to replace Weiner and Hanna with nominees Fabian Blank and Peter J. Clemens IV (collectively “Harbert Directors”).2 (Id.) And to accomplish this

1 Weiner is a co-founder of the Company and has served as its President since 1996. (Compl. ¶ 25.) Hanna, a Doctor of Microbiology, was first elected to the Board in January 2017. (Id. ¶ 26.) 2 Before their election to the Board, Blank had held executive management roles in various health care companies while Clemens had held similar executive management roles in the financial services industry. See 2019 Press Release, at 7–8. objective, Harbert promulgated the following three proxy solicitations to Enzo’s shareholders. (Id.) First, in its initial September 17, 2019 Press Release (“2019 Press Release”) announcing the proxy contest, Harbert stated that the Harbert Directors: (1) were eminently qualified and “independent candidates,” (2) that they had been selected following “an extensive search,” (3)

that the Harbert Directors had “already studied” the Company’s challenges, and (4) that they could immediately help improve the Company’s business prospects. (Compl. Ex. A (“2019 Press Release”), ECF 2.) Second, on December 9, 2019, Harbert promulgated a public letter to Enzo’s shareholders (“2019 Shareholder Letter”) which reiterated the statements made in the 2019 Press Release. (Compl. Ex. B (“2019 Shareholder Letter”), ECF 2.) The 2019 Shareholder Letter, for example, stated that the Harbert Directors were “independent candidates” whose “vast expertise and extensive networks” would substantially benefit Enzo and its shareholders. (Id.) Finally, in January 2020, Harbert released a lengthy public presentation (“2020

Presentation”) that set forth its case for corporate governance reform (Compl. Ex. C (“2020 Presentation”), ECF 2) and shortly thereafter, circulated a letter to Enzo’s shareholders (“2020 Shareholder Letter”) echoing similar statements that had already been made in prior proxy solicitations. (Compl. Ex. D (“2020 Shareholder Letter”), ECF 2.) As relevant here, the 2020 Presentation and 2020 Shareholder Letter repeated the lofty representations about the Harbert Directors’ qualifications to serve on the Board. Following these proxy solicitations, in January 2020, three proxy advisory firms—Egan- Jones Proxy Services, Institutional Shareholder Services Inc., and Glass, Lewis & Co.—endorsed the Harbert Directors’ candidacies for the Board. (Compl. ¶¶ 36–37.) III. The Harbert Directors’ Election On January 28, 2020, three days prior to the 2019 Meeting, Enzo issued a press release announcing that it would delay the 2019 Meeting from January 31 to February 25. (Id. ¶ 38.) In that same press release, Enzo proposed to its shareholders that they: (1) vote to elect the Harbert Directors, (2) expand the size of the Board, and (3) fill the additional Board seats with

Weiner and another independent director. (Id.) In response to this Eleventh Hour adjournment, Harbert filed an action against Enzo in the Southern District of New York on February 5, 2020, claiming violations of Section 14(a) of the Exchange Act and breach of fiduciary duties. (Id. ¶ 41.) As it turned out, though, the 2019 Meeting went ahead as scheduled on February 25. (Id. ¶ 42.) There, Enzo’s shareholders voted to elect the Harbert Directors to the Board and rejected the Company’s proposal to increase the Board’s size. (Id.) Five months later, on July 17, 2020, Harbert voluntarily dismissed its lawsuit against the Company. (Id. ¶ 3.) IV.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

J. I. Case Co. v. Borak
377 U.S. 426 (Supreme Court, 1964)
TSC Industries, Inc. v. Northway, Inc.
426 U.S. 438 (Supreme Court, 1976)
Virginia Bankshares, Inc. v. Sandberg
501 U.S. 1083 (Supreme Court, 1991)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Studebaker Corporation v. Richard D. Gittlin
360 F.2d 692 (Second Circuit, 1966)
Natalia Makarova v. United States
201 F.3d 110 (Second Circuit, 2000)
Rombach v. Chang
355 F.3d 164 (Second Circuit, 2004)
ATSI Communications, Inc. v. Shaar Fund, Ltd.
493 F.3d 87 (Second Circuit, 2007)
Beck v. Dobrowski
559 F.3d 680 (Seventh Circuit, 2009)
Pantry Pride, Inc. v. Rooney
598 F. Supp. 891 (S.D. New York, 1984)
Police & Fire Retirement System v. Safenet, Inc.
645 F. Supp. 2d 210 (S.D. New York, 2009)
Stedman v. Storer
308 F. Supp. 881 (S.D. New York, 1969)
Diceon Electronics, Inc. v. Calvary Partners, L.P.
772 F. Supp. 859 (D. Delaware, 1991)
In Re Marsh & McLennan Companies, Securities Litigation
536 F. Supp. 2d 313 (S.D. New York, 2007)
CNW Corp. v. Japonica Partners, L.P.
776 F. Supp. 864 (D. Delaware, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
Enzo Biochem, Inc. v. Harbert Discovery Fund, LP, Counsel Stack Legal Research, https://law.counselstack.com/opinion/enzo-biochem-inc-v-harbert-discovery-fund-lp-nysd-2021.